


excelra

Where data means more

Drug Repurposing Services




Drug Repurposing or Repositioning (DR) is a strategy in drug development that aims at identifying new therapeutic opportunities for existing drugs. Repurposing has proven to be an effective and efficient strategy for Pharma and Biotech companies looking to augment their portfolio of approved, as well as investigational drugs. DR significantly reduces the time and costs required to bring a drug to the market, especially when compared to the high investment and risk-prone nature of traditional de novo drug discovery.


Drug Repurposing at Excelra

Excelra works at the cutting-edge of in silico drug repurposing; applying Computational Biology, Computational Chemistry, Machine Learning (ML) and Deep Learning-based Solutions, driven through our proprietary

Global Repurposing Integrated Platform (GRIP)



The output from GRIP is analysed by subject-matter experts to build robust scientific hypotheses establishing the potential therapeutic role of a given drug(s) in an alternate indication.



Our In silico Drug Repurposing Workflow

- 1 **Input:** Compound target pair
- 2 **GRIP**
- 3 **Identifying, Filtering & Short-listing Drug-Disease Associations**
- 4 **Frequency table with alternative indications**


Mesh Tree	Mesh Term	Interactome	Pathways	...	Total	Status
Liver Disease (Tier III Indication)	Non-alcoholic steatohepatitis	✓	✓	...	X	Clinical
Neoplasms (Tier II Indication)	Pancreatic neoplasms	✓	✓	...	Y	Clinical
Nervous System Disease (Tier III Indication)	Multiple sclerosis	✓		...	Z	Clinical

- 5 **Bining & Profiling**

- 6 **Final Short-listed Indications**

- Indications with strong biological evidence
- Focus on partner's therapeutic interest

Our Drug Repurposing Solutions



The Excelra Edge

Our Drug Repurposing Solutions synergistically combine flexible and scalable analytical pipelines, with manual data-driven analysis conducted by our in-house subject matter experts. The drug is holistically analysed from a chemical, biological and clinical perspective to uncover novel insights. The engagement with our clients is customized and collaborative, and is based on their bespoke needs.

Advantages we bring:



Our Experience & Success Stories

Excelra has successfully delivered 100+ projects till date in rescuing as well as creating extra value out of existing assets for its global Pharma and Biotech partners.

8+ years of experience in small molecules and biologics

9 recommendations validated in pre-clinical phase

12 recommendations currently in pre-clinical evaluation with promising outcomes

3 recommendations advanced to IND enabling & Clinical stages of development

Our Clients



Innovator Pharma and Biotech companies




Generic Pharma and Biotech companies



Veterinary Pharma and Biotech companies

You may also be interested in our allied service offerings:

-  Target Identification, Prioritization and Dossier Services
-  AI-based Indication Prioritization and Drug Combination Prediction
-  Biomarker Discovery and Patient Stratification
-  Biology Data Curation and Structuring



Where data means more

excelra

SAN FRANCISCO • BOSTON • LONDON • GHENT/GENT • UTRECHT • HYDERABAD

Connect with our experts: marketing@excelra.com

www.excelra.com